News
From investments to outcomes, stay connected to the people and companies transforming Healthtech with us.
Type:
Compagnie:
Fund:
L’industrie Medtech, terrain de jeu idéal pour le capital-investissement – Décideurs Magazine – Paroles d’experts
L’industrie Medtech, terrain de jeu idéal pour le capital-investissement – Décideurs Magazine – Paroles d’experts
Lauxera collecte 520 m€ dans la healthtech – Les Echos – Capital Finance
Lauxera collecte 520 m€ dans la healthtech – Les Echos – Capital Finance
Lauxera Capital closes €520M fundraising to propel European medtech – Mugglehead
Lauxera Capital closes €520M fundraising to propel European medtech – Mugglehead
Lauxera Closes €520M Fund as European Healthtech Investors Push for U.S. Scale – Europe Says
Lauxera Closes €520M Fund as European Healthtech Investors Push for U.S. Scale – Europe Says
The sovereignty battle is lost’: why european healthtech still needs america – The French Tech Journal
The sovereignty battle is lost’: why european healthtech still needs america – The French Tech Journal
Lauxera closed a €520m healthtech fund in under 18 months. Here is how it did it – TFN
Lauxera closed a €520m healthtech fund in under 18 months. Here is how it did it – TFN
How a diversified LP base drove Lauxera’s fund ll close – RealDeals
How a diversified LP base drove Lauxera’s fund ll close – RealDeals
Lauxera Capital Partners closes fund ll, at €520m – vcwire.tech
Lauxera Capital Partners closes fund ll, at €520m – vcwire.tech
Lauxera Capital Partners: €520 million fund raised for european healthtech expansion – Pulse 2.0
Lauxera Capital Partners: €520 million fund raised for european healthtech expansion – Pulse 2.0
Lauxera doubles down on european healthtech scale-up with €520m fund ll close – Investors in healthcare
Lauxera doubles down on european healthtech scale-up with €520m fund ll close – Investors in healthcare
Lauxera boucle son 2e fonds healthtech à 520 m€ – Biotech Finances
Lauxera boucle son 2e fonds healthtech à 520 m€ – Biotech Finances
Lauxera sursouscrit un fonds de 520 millions pour accélérer les medtech européennes aux Etats-Unis – Maddyness
Lauxera sursouscrit un fonds de 520 millions pour accélérer les medtech européennes aux Etats-Unis – Maddyness
Lauxera double de taille pour son deuxième fonds, clôturé à 520 millions d’euros – l’Agefi
Lauxera double de taille pour son deuxième fonds, clôturé à 520 millions d’euros – l’Agefi
Lauxera Capital Partners clôture son fonds growth ll à 520 m€, dépassant son objectif initial- Décideurs Magazine
Lauxera Capital Partners clôture son fonds growth ll à 520 m€, dépassant son objectif initial- Décideurs Magazine
Lauxera Capital double la taille de son fonds – CFNEWS
Lauxera Capital double la taille de son fonds – CFNEWS
Lauxera Capital Partners Raises €520 million Fund II to Scale a New Generation of European Healthtech Leaders – Press release
Lauxera Capital Partners Raises €520 million Fund II to Scale a New Generation of European Healthtech Leaders – Press release
Lauxera Capital Partners raises a hefty €520M for health, medtech companies – Fierce Biotech
Lauxera Capital Partners raises a hefty €520M for health, medtech companies – Fierce Biotech
Pierre Moustial at Check-up Santé on BFM Business
Pierre Moustial at Check-up Santé on BFM Business
Lauxera Capital Partners supports Matrix One’s strategic expansion with two acquisitions, strengthening its life sciences software platform
Lauxera Capital Partners supports Matrix One’s strategic expansion with two acquisitions, strengthening its life sciences software platform
Lauxera Capital Partners appoints Dr. Oern Stuge as Senior Advisor – Press release
Lauxera Capital Partners appoints Dr. Oern Stuge as Senior Advisor – Press release
Lauxera raises over €400 million to support the global expansion of European healthtechs
Lauxera raises over €400 million to support the global expansion of European healthtechs
Lauxera raises over €400m for its second vintage
Lauxera raises over €400m for its second vintage
Lauxera tops target for sophomore fund
Lauxera tops target for sophomore fund
Terumo to acquire OrganOx Limited, a leading innovator in organ preservation devices, marking strategic entry into the organ transplantation-related sector
Terumo to acquire OrganOx Limited, a leading innovator in organ preservation devices, marking strategic entry into the organ transplantation-related sector
Oxford university spinout OrganOx sold to Japanese group Terumo for $1.5bn
Oxford university spinout OrganOx sold to Japanese group Terumo for $1.5bn
La cession d’Organox à un industriel offre une première sortie éclatante à Lauxera Capital – L’Agefi
La cession d’Organox à un industriel offre une première sortie éclatante à Lauxera Capital – L’Agefi
OrganOx réalise l’une des plus importantes sorties de fonds dans le secteur des technologies médicales au Royaume-Uni, générant un rendement record pour BGF
OrganOx réalise l’une des plus importantes sorties de fonds dans le secteur des technologies médicales au Royaume-Uni, générant un rendement record pour BGF
Terumo Buying Organ Tech Provider OrganOx for$1.5 Billion
Terumo Buying Organ Tech Provider OrganOx for$1.5 Billion
Lauxera Capital Partners cède OrganOx pour 1,5 Md $
Lauxera Capital Partners cède OrganOx pour 1,5 Md $
Lauxera enregistre sa première sortie
Lauxera enregistre sa première sortie
Terumo to acquire Organox Limited for approximately USD $1.5 billion
Terumo to acquire Organox Limited for approximately USD $1.5 billion
Lauxera Capital Partners is proud to announce its investment in Antaros, a leading Swedish Imaging Drug Development Partner
Lauxera Capital Partners is proud to announce its investment in Antaros, a leading Swedish Imaging Drug Development Partner
Lauxera Capital Partners Co-Leads a $142m Equity Investment Into OrganOx
Lauxera Capital Partners Co-Leads a $142m Equity Investment Into OrganOx
Lauxera Invests €50m in Acandis, a German, Neurovascular Medical Device Company Dedicated to the Prevention and Treatment of Stroke
Lauxera Invests €50m in Acandis, a German, Neurovascular Medical Device Company Dedicated to the Prevention and Treatment of Stroke
Lauxera Capital Partners Acquires Galen Data
Lauxera Capital Partners Acquires Galen Data
Synovo Group secures €12 million funding from Lauxera Capital Partners to accelerate growth and innovation in Healthtech transport software
Synovo Group secures €12 million funding from Lauxera Capital Partners to accelerate growth and innovation in Healthtech transport software
Biomedicaments : Verdot to invest €10 million in new plant in Puy-de-Dôme
Biomedicaments : Verdot to invest €10 million in new plant in Puy-de-Dôme
Natural cycles: $55m to consolidate its leadership in digital contraceptive health
Natural cycles: $55m to consolidate its leadership in digital contraceptive health
Natural Cycles Closes $55m Series C Financing Round Led by Lauxera Capital Partners
Natural Cycles Closes $55m Series C Financing Round Led by Lauxera Capital Partners
Newsweek: World’s Best Digital Health Companies 2024
Newsweek: World’s Best Digital Health Companies 2024
Impact and financial returns: a winning combination
Impact and financial returns: a winning combination
Pierre Moustial on BFM Business – Check-up Santé
Pierre Moustial on BFM Business – Check-up Santé
Lauxera’s charitable partnership with Institut Imagine is explained in this interview with Stanislas Lyonnet and Pierre Moustial
Lauxera’s charitable partnership with Institut Imagine is explained in this interview with Stanislas Lyonnet and Pierre Moustial
Lauxera Capital Partners signs a partnership with Institut Imagine to fund groundbreaking research into rare diseases
Lauxera Capital Partners signs a partnership with Institut Imagine to fund groundbreaking research into rare diseases
OSPI wants to optimize the use of hospital data with AI
OSPI wants to optimize the use of hospital data with AI
Creation of Ospi, the result of the merger between Groupe PSIH and Collective Thinking
Creation of Ospi, the result of the merger between Groupe PSIH and Collective Thinking
Lauxera Capital Partners invests €17 million in Swedish regenerative medicine leader BioLamina AB
Lauxera Capital Partners invests €17 million in Swedish regenerative medicine leader BioLamina AB
Lauxera Capital Partners has led a £25m growth investment into OrganOx
Lauxera Capital Partners has led a £25m growth investment into OrganOx
Caresyntax, Relyens and Intel are collaborating to launch the Connected Surgery program
Caresyntax, Relyens and Intel are collaborating to launch the Connected Surgery program
Purification: Auvergne, France-based Verdot changes hands
Purification: Auvergne, France-based Verdot changes hands
Lauxera Capital Partners invests €10m in German Medtech software company Matrix Requirements
Lauxera Capital Partners invests €10m in German Medtech software company Matrix Requirements
Lauxera Capital Partners – Press release – Final closing
Lauxera Capital Partners – Press release – Final closing
Leading MedTech Lifen raises €50M
Leading MedTech Lifen raises €50M
Pierre Moustial Interview
Pierre Moustial Interview
Caresyntax Extends Series C to Total Raise of $130 million
Caresyntax Extends Series C to Total Raise of $130 million
Press Release Groupe PSIH
Press Release Groupe PSIH
Sifted – Caresyntax secures $100m for AI hospital operating tech
Sifted – Caresyntax secures $100m for AI hospital operating tech
Fierce Healthtech – Caresyntax hauls in $100m to expand
Fierce Healthtech – Caresyntax hauls in $100m to expand
Fierce Biotech – LUMICKS snags £93M for its molecular tweezers and cell therapy hardware
